Fabrication and characterization of novel PLA/CH/GelMA/hydroxyapatite electrospun nanofibers for bone tissue regeneration
Bozdag M., Avci T., Izgordu S., Baykara D., Pilavci E., Eleman B.
Animal Study, published in RSC Adv (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- RSC Adv (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41725825
- PMCID
- PMC12921472
- DOI
- 10.1039/d5ra09292b
Abstract (original English)
This study focuses on the fabrication and comprehensive characterization of electrospun nanofibrous scaffolds composed of polylactic acid (PLA), chitosan (CH), gelatin methacryloyl (GelMA), and varying concentrations of hydroxyapatite (HAP) nanoparticles (0.1, 0.3, and 0.5% w/v) for potential applications in bone tissue engineering. Unlike previous studies utilizing binary or ternary systems, this work introduces a novel quadri-composite scaffold designed to overcome individual material limitations through synergistic effects: PLA provides the mechanical backbone, chitosan ensures hydrophilicity and antimicrobial potential, GelMA enhances cell adhesion via RGD motifs, and HAP serves as the osteoconductive mineral phase. The structural, thermal, mechanical, swelling, degradation, and biological properties of the nanofibers were investigated using SEM, FT-IR, DSC, and tensile testing. Among the tested formulations, the nanofibers containing 0.3% HAP exhibited the most balanced properties, with a tensile strength of 0.50 ± 0.18 MPa and elongation at break of 14.82 ± 6.93%, indicating optimal mechanical flexibility. These fibers also demonstrated improved thermal stability, controlled swelling behavior, and a degradation profile suitable for bone healing. In vitro biocompatibility studies using human osteoblast (hFOB) cells showed that while lower HAP content supported initial atta
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.